Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Overview

The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.

Eligibility

Inclusion Criteria:

• Individuals with < 34 0/7 weeks of gestation.
• Individuals with severe preeclampsia or HELLP features.

Exclusion Criteria:

• Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).
• Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.